SCHEMBL25801832

SCHEMBL25801832

CCC1(C(C)C)Cc2cccnc2[C@H]1N

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.33
PTPN11 Q06124 1/20 0.33
DPP8 Q6V1X1 1/20 0.32
DPP9 Q86TI2 1/20 0.32
CHRM2 P08172 2/20 0.30
CHRM4 P08173 2/20 0.30
CHRM5 P08912 2/20 0.30
CHRM1 P11229 2/20 0.30
CHRM3 P20309 2/20 0.30
HRH1 P35367 1/20 0.30
CXCR4 P61073 1/20 0.30
ADRA2A P08913 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C19 P33261 1/20 0.30
KMT2A Q03164 1/20 0.30
PDK2 Q15119 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25800896 0.79 KCNH2 (0.33) KCNH2PTPN11CXCR4PDK2
SCHEMBL25808452 0.79 KCNH2 (0.35) KCNH2PTPN11CXCR4ADRA2AADRA2B
SCHEMBL24152482 0.78 CHRNA7 (0.33) KCNH2PTPN11PDK2
SCHEMBL25803172 0.77 PTPN11 (0.34) KCNH2PTPN11DPP8DPP9
SCHEMBL22393733 0.76 HTR2A (0.38) KCNH2CHRM1CHRM3HRH1ADRA2A
SCHEMBL24151276 0.73 KCNH2 (0.34) KCNH2PTPN11KMT2A
SCHEMBL24388776 0.73 KCNH2 (0.34) KCNH2PTPN11KMT2A
SCHEMBL25801830 0.71 PTPN11 (0.33) KCNH2PTPN11
SCHEMBL25802341 0.71 PTPN11 (0.33) PTPN11
SCHEMBL24091167 0.69 PTPN11 (0.46) KCNH2PTPN11HRH1CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212180-A1 SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212180-A1 SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF PTPN5, PTPN1, PTPN2 KCNH2 2405/4885PTPN11 5/4885DPP8 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.